Western Blot – News and Features

In this article, Dr. Kenneth Oh discusses how a comprehensive qPCR–western blot–multiplex assay workflow can revolutionize drug discovery approaches.

This article explores the current state of Lyme disease testing and how improvements could be made in the future to improve time to diagnosis.

In this article, we will consider how polyacrylamide gel electrophoresis (PAGE) works, how it can be interpreted and some of its applications.

Renowned scientists and engineers from the Massachusetts Institute of Technology (MIT) have developed and tested a capsule-based system for oral delivery of mRNA therapeutics.

Antibodies are immunological proteins that play fundamental roles in host defense against infectious agents such as viruses, bacteria and fungi. Two types of antibodies – polyclonal and monoclonal – provide research scientists with distinct ways to detect or quantify target antigens largely due to differences in specificity and affinity. In this article, we describe polyclonal and monoclonal antibodies in more detail and consider how each type may be used for various applications.

There are many reasons you may need to determine the presence (or absence) and size of a given protein within a sample, potentially against a background of many others. The western blot is one such technique that offers these capabilities. In this article, we discuss what western blots are, how they are performed, what they show us and how they differ to related techniques.

A blood test that quantifies the protein ACE2, the cellular protein which allows entry of the virus into cells, as well as ACE2 fragments, produced as a result of interaction with the virus, could be an effective method for monitoring SARS-CoV-2 infection.

The European Proteomics Infrastructure Consortium providing Access, or EPIC-XS, started in January 2019. It brings together a consortium of world-leading, highly innovative European proteomics facilities with the shared goal of supporting excellent life sciences research in Europe. In this article, Martina O'Flaherty provides an overview of some of the successes of the consortium so far.

Technology Networks recently spoke with Jean-François Bellec, ProteinSimple applications scientist, to learn about Bio-Techne’s history and how its solutions enable researchers to work efficiently and ensure accuracy in their experiments. In this interview, Jean-François also highlights how the company’s offerings have supported researchers throughout the COVID-19 pandemic.

It is recognized that Parkinson's disease patients are more likely to develop melanoma than the general population. Scientists now report a molecular link between the two diseases in the form of protein aggregates known as amyloids.